A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results
作者
Pietro Lampertico,Marı́a Buti,Alnoor Ramji,Scott Fung,Sang Hoon Ahn,Wan‐Long Chuang,Seung Kew Yoon,Jia‐Horng Kao,Chi-Yi Chen,Edward Tam,Mandana Khalili,Ho Bae,Xiaoli Ma,Won Young Tak,John F. Flaherty,Anuj Gaggar,Vithika Suri,Susanna K. Tan,Yang Liu,George Y. Wu